DBPR108 Tablets in Type 2 Diabetes Mellitus Patients

NCT ID: NCT04124484

Last Updated: 2019-10-15

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 276 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-10-17
• Study Completion Date: 2019-06-28

Brief Summary

This study evaluate DRBP108 in the treatment of type 2 diabetes mellitus. The patients were randomly allocated to four groups: 50 mg, 100 mg, 200 mg and placebo group.

Detailed Description

This study was to evaluate DRBP108 in the treatment of type 2 diabetes mellitus. A total of 268 subjects were randomly allocated to four treatment arms: 50 mg, 100 mg, 200 mg or placebo group, in a 1:1:1:1 ratio.

Conditions

Type 2 Diabetes Mellitus

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

50mg group

Participants received one 50mg of DBPR108 tablet and two placebos matching DBPR108 100mg under fasted conditions for one day.

Group Type: EXPERIMENTAL

DBPR108 tablet(50mg), Placebo matching DBPR108 tablet(100mg)

Intervention Type: DRUG

One DBPR108 tablet(50mg) administered orally once a day + Two Placebos matching DBPR108 tablet(100mg) administered orally once a day for 12 weeks

100mg group

Participants received one 100mg of DBPR108 tablet and two placebos matching DBPR108 50mg and 100mg under fasted conditions for one day.

Group Type: EXPERIMENTAL

DBPR108 tablet(100mg), Placebo matching DBPR108 tablet(50mg), Placebo matching DBPR108 tablet(100mg)

Intervention Type: DRUG

One DBPR108 tablet(100mg) administered orally once a day + One Placebo matching DBPR108 tablet(100mg) administered orally once a day + One Placebo matching DBPR108 tablet(50mg) administered orally once a day for 12 weeks

200mg group

Participants received two 100mg of DBPR108 tablets and one placebo matching DBPR108 50mg under fasted conditions for one day.

Group Type: EXPERIMENTAL

DBPR108 tablet(100mg), Placebo matching DBPR108 tablet(50mg)

Intervention Type: DRUG

Two DBPR108 tablets(100mg) administered orally once a day + One Placebo matching DBPR108 tablet(50mg) administered orally once a day for 12 weeks

placebo group

Participants received two placebo matching DBPR108 100mg and one placebo matching DBPR108 50mg

Group Type: PLACEBO_COMPARATOR

Placebo matching DBPR108 tablet(100mg), Placebo matching DBPR108 tablet(50mg)

Intervention Type: DRUG

Two Placebos matching DBPR108 tablet(100mg) administered orally once a day + One Placebo matching DBPR108 tablet(50mg) administered orally once a day for 12 weeks

Interventions

DBPR108 tablet(50mg), Placebo matching DBPR108 tablet(100mg)

One DBPR108 tablet(50mg) administered orally once a day + Two Placebos matching DBPR108 tablet(100mg) administered orally once a day for 12 weeks

Intervention Type: DRUG

DBPR108 tablet(100mg), Placebo matching DBPR108 tablet(50mg), Placebo matching DBPR108 tablet(100mg)

One DBPR108 tablet(100mg) administered orally once a day + One Placebo matching DBPR108 tablet(100mg) administered orally once a day + One Placebo matching DBPR108 tablet(50mg) administered orally once a day for 12 weeks

Intervention Type: DRUG

DBPR108 tablet(100mg), Placebo matching DBPR108 tablet(50mg)

Two DBPR108 tablets(100mg) administered orally once a day + One Placebo matching DBPR108 tablet(50mg) administered orally once a day for 12 weeks

Intervention Type: DRUG

Placebo matching DBPR108 tablet(100mg), Placebo matching DBPR108 tablet(50mg)

Two Placebos matching DBPR108 tablet(100mg) administered orally once a day + One Placebo matching DBPR108 tablet(50mg) administered orally once a day for 12 weeks

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Subjects who meet the World Health Organization(WHO) (1999) criteria for the diagnosis and classification criteria for type 2 diabetes;
• 18 ≤ age ≤ 75 years old, male or female;
• One of the following conditions:

1. Initial diagnosis of type 2 diabetes mellitus;

2. Patients who with type 2 diabetes diagnosed within 2 years before screening period and are treated with single-agent oral hypoglycemic agents until screening, and do not take the medicine regularly for at least 8 weeks (i.e., continuous medication for <1 week);

• 19kg/m^2 ≤ Body Mass Index（BMI ）≤ 35kg/m^2;
• 7.0% ≤ HbA1c ≤ 10.0%;
• Female subjects of childbearing age are negative in pregnancy test;
• All the subjects do not have a fertility plan during and three month after the trial;
• Subjects who fully understand the test content and possible adverse reactions and voluntarily participate in the trial and sign the informed consent form;

Exclusion Criteria

• FPG > 15 mmol/L;
• Systolic blood pressure > 160 mmHg or diastolic blood pressure > 100 mmHg during screening period;
• Those who are known to be positive for HIV and syphilis;
• known active hepatitis B virus infection, hepatitis C virus infection;
• For patients with obvious liver diseases and chronic liver diseases, AST or ALT in screening stage was twice the normal upper limit.
• In patients with renal insufficiency, serum creatinine at screening stage was 1.5 times higher than the upper limit of normal value;
• Leukocyte and hemoglobin < lower limit of normal value, triglyceride > 5.7 mmol/L in screening stage;
• With diabetic acute complications (including diabetic ketoacidosis, hypertonic non-ketoacid diabetic coma, lactic acidosis and hypoglycemic coma), chronic complications (proliferative diabetic retinopathy, diabetic nephropathy);
• Use of insulin, pioglitazone, DPP-4 inhibitor, GLP-1 receptor agonist or any combination of two or more oral hypoglycemic drugs within 8 weeks before screening time.
• Those who need insulin therapy;
• Using and Used of glucocorticoids within 2 weeks before screening time.
• without a pacemaker, the 12-lead ECG showed II or III degree atrioventricular block, long QT syndrome or corrected QT interval （QTc）>500ms or atrial fibrillation during the screening period;
• History of epilepsy, mental illness, major depression, or previous thyroid function abnormal and still being treated, or those with organ transplants, severe chronic lung disease, and other serious heart disease, cerebrovascular disease, blood disease;
• Inflammatory bowel disease, colon ulcer, partial intestinal obstruction or chronic intestinal diseases associated with digestive and absorption diseases;
• Active pancreatitis, cholecystitis, gallstones and other digestive diseases;
• History of severe hypoglycemia;
• History of allergies with similar drugs (DPP-4 inhibitors) or those who are judged by the investigator to be allergic to the test drug;
• Pregnancy, lactating women;
• Subjects who are participating in other clinical trials or who have participated in other drug trials within 3 months prior to screening;
• Not suitable for this clinical trial judged by the investigator.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

First Hospital of Peking Unversity

Beijing, Beijing Municipality, China

Countries

China

References

Wang W, Yao J, Guo X, Guo Y, Yan C, Liu K, Zhang Y, Wang X, Li H, Wen Z, Wang X, Li S, Xiao X, Liu W, Li Z, Zhang L, Shao S, Ye S, Qin G, Li Y, Li F, Zhang X, Li X, Peng Y, Deng H, Xu X, Zhou L, Huang Y, Cao M, Xia X, Shi M, Dou J, Yuan J. Efficacy and safety of DBPR108 monotherapy in patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled, phase II clinical trial. Curr Med Res Opin. 2020 Jul;36(7):1107-1115. doi: 10.1080/03007995.2020.1761311. Epub 2020 May 12.

Reference Type: DERIVED

PMID: 32338063 (View on PubMed)

Other Identifiers

CSPC/HA1117/PRO-II

Identifier Type: -

Identifier Source: org_study_id